The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identification of patient population with longer survival when treated with S-1 plus cisplatin via predictive enrichment strategy analysis of the FLAGS phase III trial.
 
Jaffer A. Ajani
Honoraria - Bayer; Five Prime Therapeutics; Genentech; Lilly/ImClone; Novartis; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; MedImmune; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
Travel, Accommodations, Expenses - Bayer; Five Prime Therapeutics; Novartis
 
Madoka Takeuchi
Travel, Accommodations, Expenses - AnGes
 
Masahiro Takeuchi
Honoraria - Shionogi
Consulting or Advisory Role - Abbvie; Astellas Pharma; Hisamitsu Pharmaceutical; Taiho Pharmaceutical